News
Click here for news in Danish.
December 18, 2020 | Company Announcements
Bavarian Nordic Announces Top-line Results from Phase 2 Clinical Trial of BN-Brachyury in ChordomaDecember 16, 2020 | Company Announcements
Bavarian Nordic Secures Second Part of Smallpox Vaccine Order from the U.S. GovernmentDecember 08, 2020 | Company Announcements
Bavarian Nordic Introduces New Employee Incentive Program November 16, 2020 | Company Announcements
Bavarian Nordic Announces Major Shareholder Notification from Invesco Ltd.November 13, 2020 | Company Announcements
CORRECTION: Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with suchNovember 12, 2020 | Press Releases
Health Canada Extends Approval of IMVAMUNE to Immunization against Monkeypox and Orthopox VirusesNovember 11, 2020 | Company Announcements
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with suchNovember 11, 2020 | Company Announcements
Bavarian Nordic Announces Interim Results for the First Nine Months of 2020 October 09, 2020 | Company Announcements
Bavarian Nordic Announces Appointment of Anu Helena Kerns as Executive Vice President, People and OrganizationSeptember 02, 2020 | Company Announcements
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program and Termination of Share Buy-Back ProgramAugust 26, 2020 | Company Announcements
Bavarian Nordic Launches Share Buy-Back Program to Hedge Incentive Scheme ObligationsAugust 26, 2020 | Company Announcements
Bavarian Nordic Announces First Half 2020 Results August 24, 2020 | Company Announcements
Bavarian Nordic Announces Positive Topline Results from Phase 3 Clinical Study of Freeze-dried Smallpox VaccineAugust 05, 2020 | Press Releases
Bavarian Nordic Announces the Launch of Distribution and Marketing of RabAvert® in the U.S. Supported by a U.S. Commercial Team July 22, 2020 | Company Announcements
Bavarian Nordic and AdaptVac Sign Final License Agreement on COVID-19 VaccineJuly 03, 2020 | Company Announcements
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with suchJuly 01, 2020 | Company Announcements
Bavarian Nordic Announces European Marketing Authorization for Ebola VaccineJune 18, 2020 | Company Announcements
Bavarian Nordic and Valneva Announce Marketing and Distribution Partnership June 12, 2020 | Company Announcements
Bavarian Nordic to Manufacture Additional Ebola Vaccines for JanssenJune 12, 2020 | Company Announcements
Bavarian Nordic A/S – Report on the Results of the Annual General Meeting, held June 12, 2020June 08, 2020 | Company Announcements
Bavarian Nordic Announces Topline Results from Phase 1 Clinical Trial of Equine Encephalitis Virus Vaccine May 29, 2020 | Company Announcements
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with suchMay 29, 2020 | Company Announcements
Bavarian Nordic Announces that Janssen has Received Positive CHMP Opinion for its Investigational Preventative Ebola Vaccine RegimenMay 25, 2020 | Company Announcements
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with suchMay 25, 2020 | Company Announcements
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise